Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Good pharmacovigilance practices: technology enabled.

Robert C Nelson1, Bruce Palsulich, Victor Gogolak

  • 1RCN Associates, Inc., Annapolis, Maryland 21403, USA. rcnelson@rcnrx.com

Drug Safety
|June 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2017 Letter From the American Chiropractic Board of Sports Physicians President.

Journal of chiropractic medicine·2018
Same author

Chiropractic and concussion in sport: a narrative review of the literature.

Journal of chiropractic medicine·2014
Same author

The FDA drug safety surveillance program: adverse event reporting trends.

Archives of internal medicine·2011
Same author

Accelerating statistical research in drug safety.

Pharmacoepidemiology and drug safety·2006
Same author

Rosuvastatin: an independent analysis of risks and benefits.

MedGenMed : Medscape general medicine·2006
Same author

Delegation.

Optometry (St. Louis, Mo.)·2002
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

A rigorous process, the Good Pharmacovigilance Process (GPVP), enhances drug safety by effectively detecting adverse reactions. This structured approach, supported by technology, ensures reliable drug safety signaling.

Area of Science:

  • Pharmacovigilance
  • Drug Safety
  • Risk Management

Background:

  • Spontaneous reports are crucial for drug safety assessment.
  • Effective assessment requires a defined and rigorous process.
  • Existing frameworks can be enhanced for better risk management.

Purpose of the Study:

  • To propose the Good Pharmacovigilance Process (GPVP) as a framework for effective spontaneous report assessment.
  • To outline specific practices and technological enablers for GPVP.
  • To integrate GPVP within broader postmarketing surveillance and risk management strategies.

Main Methods:

  • Defined GPVP as a subset of Good Postmarketing Surveillance Process (GPMSP).
  • Incorporated specific practices: rules-based triage, active query prompts, contextual evaluation, statistical checks, case-series analyses, and signal work-up templates.

Related Experiment Videos

  • Utilized state-of-the-art web-based systems with analytical engines, workflow, and audit trails.
  • Main Results:

    • GPVP practices efficiently detect and alert professionals to new adverse reaction information.
    • Applied technology, including analytical engines and workflow systems, supports validated drug safety signaling.
    • A holistic process approach prevents misinterpretation of isolated technical alerts.

    Conclusions:

    • The GPVP provides a structured and effective method for assessing spontaneous reports.
    • Technological enablement is key to efficient and reliable drug safety signaling.
    • Pharmacovigilance is an essential clinical component of pharmacoepidemiology and risk management.